HIBERCELL
HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis. The company was founded in 2019 and is based in New York.
HIBERCELL
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
2019-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.hibercell.com
Total Employee:
11+
Status:
Active
Contact:
212-601-2800
Email Addresses:
[email protected]
Total Funding:
158.15 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Wordpress Plugins
Similar Organizations
Abdera Therapeutics
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-08-16 | Genuity Science | Genuity Science acquired by HiberCell | 100 M USD |
| 2020-07-07 | Biothera | Biothera acquired by HiberCell | N/A |
Investors List
ARCH Venture Partners
ARCH Venture Partners investment in Series B - HiberCell
Huizenga Capital Management
Huizenga Capital Management investment in Series B - HiberCell
Magnetic Ventures
Magnetic Ventures investment in Series B - HiberCell
Hercules Capital
Hercules Capital investment in Debt Financing - HiberCell
Monashee Investment Management
Monashee Investment Management investment in Series B - HiberCell
Trinitas Capital
Trinitas Capital investment in Series B - HiberCell
Bristol Myers Squibb
Bristol Myers Squibb investment in Series B - HiberCell
Celgene
Celgene investment in Series A - HiberCell
ARCH Venture Partners
ARCH Venture Partners investment in Series A - HiberCell
Hillhouse Capital Group
Hillhouse Capital Group investment in Series A - HiberCell
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-30 | HiberCell Appoints Jonathan Lanfear as Chief Operating Officer |
Official Site Inspections
http://www.hibercell.com Semrush global rank: 7.28 M Semrush visits lastest month: 544
- Host name: 47.107.198.104.bc.googleusercontent.com
- IP address: 104.198.107.47
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "HiberCell"
HiberCell - Crunchbase Company Profile & Funding
Additionally, HiberCell has been responsible for funding research, which suggests a solid financial position to support its scientific endeavors. Furthermore, the …See details»
HiberCell, Inc. - Drug pipelines, Patents, Clinical trials
Mar 11, 2025 BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. …See details»
HiberCell Org Chart + Executive Team - The Official Board
Organizational Chart of HiberCell. HiberCell Org Chart www.hibercell.com. has 86 executives and 7 subsidiaries +1 212 601 2800; Add an executive. HiberCell News . Anything missing? We …See details»
HiberCell 2025 Company Profile | PitchBook
HiberCell is headquartered in New York, NY. What is the size of HiberCell? HiberCell has 53 total employees. What industry is HiberCell in? HiberCell’s …See details»
Hibercell - Overview, News & Similar companies | ZoomInfo.com
Who is Hibercell. HiberCell is a clinical-stage biotechnology company dedicated to the advancement of novel therapeutic candidates that overcome the foundational mol ecular …See details»
About - HiberCell
Learn about HiberCell's story, team, and investors. Toggle navigation. About . Mission; Team; Our Science . Overview; HC-7366; HC-5404See details»
Team - HiberCell
Michele Gargano, MS.c. Vice President of Clinical Operations and Program Management. “Inspiring quote goes here on rollover” José Iglesias, M.D. Chief Medical OfficerSee details»
Hibercell, Inc. Company Profile | New York, NY | Competitors ...
Find company research, competitor information, contact details & financial data for Hibercell, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
HiberCell - LinkedIn
HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity.See details»
HiberCell - Contacts, Employees, Board Members, Advisors & Alumni
HiberCell is a clinical-stage biotechnology company dedicated to the advancement of novel therapeutic agents targeting adaptive stress. ... Experience the new Crunchbase, powered by …See details»
HiberCell Overview | SignalHire Company Profile
HiberCell is a private company that has been in the industry for 6 years. The company currently specializes in the Biotechnology, Biotechnology areas. ... Organization Website: hibercell.com …See details»
HiberCell - The Org
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As “the dormancy company,” …See details»
HiberCell Company Profile - Office Locations, Competitors ... - Craft
HiberCell has 5 employees across 2 locations and $128.15 m in total funding,. See insights on HiberCell including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
HiberCell - VentureRadar
HiberCell is the first company exclusively focused on tumor dormancy detection and therapeutics. The company is developing first-in-class therapeutics that target dormant disseminated tumor …See details»
HiberCell - Funding, Financials, Valuation & Investors - Crunchbase
HiberCell is a clinical-stage biotechnology company dedicated to the advancement of novel therapeutic agents targeting adaptive stress. New. Resources. ... How much funding has this …See details»
Our Mission - HiberCell
HiberCell was launched in 2019 with investor support from ARCH Venture Partners and other leading life science investors. With our focus on targeting stress-driven vulnerabilities, we have …See details»
HiberCell launches with $60M+ to combat cancer relapse and …
Feb 7, 2019 HiberCell, a new startup focused on preventing cancer metastasis and relapse, launched Thursday with research out of Mount Sinai and $60.75 million from the likes of …See details»
New York Biotech Raises $61 Million To Keep Cancer Cells ... - Forbes
Feb 7, 2019 HiberCell, a new biotech company based in New York City, is launching with five employees and $60.75 million from ARCH Venture Partners and other investors to pursue an …See details»
Hibercell Company Profile | Management and Employees List
HiberCell is a clinical-stage biotechnology company dedicated to the advancement of novel therapeutic candidates that overcome the foundational molecular barriers that prevent patients …See details»
DNA organization offers clues for advancing stem cell therapy
3 days ago Scientists at the University of California, Riverside, have discovered how adult stem cells retain their regenerative power. The researchers demonstrate in a paper published in the …See details»